Pimonidazole
Product Specifications
UNSPSC Description
Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor[1]. Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia [2].
Target Antigen
Others
Type
Reference compound
Related Pathways
Others
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pimonidazole.html
Purity
99.07
Solubility
H2O : 1 mg/mL (ultrasonic)
Smiles
OC(CN1C=CN=C1[N+]([O-])=O)CN2CCCCC2
Molecular Weight
254.29
References & Citations
[1]Varia MA, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998 Nov;71(2):270-7.|[2]Masaki Y, et al. Imaging Mass Spectrometry Revealed the Accumulation Characteristics of the 2-Nitroimidazole-Based Agent "Pimonidazole" in Hypoxia. PLoS One. 2016 Aug 31;11(8):e0161639.Sci Rep. 2023 Apr 21;13(1):6528.|Theranostics. 2022 Apr 4;12(7):3196-3216.|Asian J Pharm Sci. 2023 Mar 20.|J Colloid Interface Sci. 2024 May:661:908-922.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-105129A/Pimonidazole-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-105129A/Pimonidazole-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
70132-50-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1484595-01 0.02 mg (E-Coli)
Recombinant Clostridium perfringens tRNA modification GTPase MnmE (mnmE)
Ask
View Details MBS1484595-02 0.02 mg (Yeast)
Recombinant Clostridium perfringens tRNA modification GTPase MnmE (mnmE)
Ask
View Details